Guanfacine
- Generic Name
- Guanfacine
- Brand Names
- Intuniv, Tenex
- Drug Type
- Small Molecule
- Chemical Formula
- C9H9Cl2N3O
- CAS Number
- 29110-47-2
- Unique Ingredient Identifier
- 30OMY4G3MK
- Background
Guanfacine, or BS 100-141, is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974.
Guanfacine was granted FDA approval on 27 October 1986.
- Indication
Guanfacine is indicated alone or as an adjunct with stimulants to treat ADHD.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Gilles de la Tourette's Syndrome, Hypertension, Migraine
Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder
- Conditions
- Intermittent Explosive DisorderChildhood AggressionOppositional Defiant DisorderAttention Deficit Disorder
- Interventions
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2018-06-13
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 11
- Registration Number
- NCT02048241
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Efficacy of GXR as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- JPM van Stralen Medicine Professional
- Target Recruit Count
- 50
- Registration Number
- NCT01985581
- Locations
- 🇨🇦
JPM van Stralen Medicine Professional Corporation, Ottawa, Ontario, Canada
PK/PD Comparison of Guanfacine ER and IR
- First Posted Date
- 2013-07-22
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- Yale University
- Target Recruit Count
- 5
- Registration Number
- NCT01904526
- Locations
- 🇺🇸
Yale Center for Clinical Investigations, Yale University, New Haven, Connecticut, United States
Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD
- Conditions
- ADHDAttention Deficit Hyperactivity Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2018-02-14
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 27
- Registration Number
- NCT01709695
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance
- Conditions
- Chronic Pain
- Interventions
- First Posted Date
- 2012-09-07
- Last Posted Date
- 2023-03-14
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT01681264
- Locations
- 🇺🇸
Center for Translational Pain Research, Boston, Massachusetts, United States
The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects
- First Posted Date
- 2012-05-17
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- Yale University
- Target Recruit Count
- 16
- Registration Number
- NCT01600885
- Locations
- 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States
🇺🇸Yale Magnetic Resonance Research Center, New Haven, Connecticut, United States
🇺🇸Veterans Affairs Hospital, West Haven, Connecticut, United States
Guanfacine in Children With Tic Disorders
- Conditions
- Tourette DisorderTourette Syndrome
- Interventions
- Drug: placebo
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Yale University
- Target Recruit Count
- 34
- Registration Number
- NCT01547000
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸Mount Sinai School of Medicine, New York, New York, United States
🇺🇸Yale Child Study Center, New Haven, Connecticut, United States
Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2019-02-05
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 22
- Registration Number
- NCT01467999
- Locations
- 🇺🇸
STARS, New York, New York, United States
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Drug: Placebo Comparator
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Shire
- Target Recruit Count
- 338
- Registration Number
- NCT01244490
- Locations
- 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸NeuroScience Inc., Herndon, Virginia, United States
🇺🇸Claghorn-Lesem Research Clinic, Houston, Texas, United States
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
- Conditions
- Pervasive Development Disorders
- Interventions
- Other: placebo
- First Posted Date
- 2010-11-10
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Yale University
- Target Recruit Count
- 62
- Registration Number
- NCT01238575
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.